CONSHOHOCKEN, Pa. – Madrigal Pharmaceuticals, Inc. (NASDAQ:), a biopharmaceutical company focused on developing treatments for nonalcoholic steatohepatitis (NASH), has announced the appointment of Mardi C. Dier as Chief Financial Officer, effective March 11, 2024.
Dier brings over two decades of financial leadership experience in the biopharmaceutical industry to her new role at Madrigal.
Dier’s extensive background includes serving as CFO at several companies, including Portola Pharmaceuticals, Ultragenyx Pharmaceutical (NASDAQ:), Inc., and Acelyrin, Inc.
During her tenure at Ultragenyx, the employee base expanded by 50%, and the company grew its global commercial presence. At Portola, Dier played a critical role in scaling the organization from a small team to a global enterprise with multiple sites and over 450 employees.
Prior to her industry roles, Dier worked in investment banking at Prudential Securities and in the audit department at KPMG Peat Marwick. She also serves on the Board of Directors for multiple pharmaceutical and healthcare companies and is an advisor for UCLA’s Anderson School of Management.
Madrigal’s CEO, Bill Sibold, expressed confidence in Dier’s capabilities, highlighting her proven track record in helping biopharmaceutical companies scale for commercial success. Dier herself is excited about the opportunity at Madrigal, noting the company’s potential to transform patient care and become a major success story in the industry.
Dier’s appointment comes as Madrigal prepares for the launch of its lead candidate, resmetirom, a once-daily, oral, liver-directed THR-β agonist aimed at treating NASH. She joined the company on February 27, 2024, as a senior advisor and will transition into her role as CFO on March 11, 2024, succeeding Alex Howarth, who will continue as a senior advisor until March 31, 2024, to ensure a smooth handover.
Madrigal’s leadership expressed gratitude to the outgoing CFO Alex Howarth for his significant contributions during a period of rapid growth and for establishing a strong financial foundation for the company.
The information in this article is based on a press release statement from Madrigal Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here